EPISODE · Dec 2, 2024 · 27 MIN
Hit It With Your Best Shot- The Case for IO in Early-Stage NSCLC in a Once in a Lifetime World
from Conversations in Lung Cancer Research · host Lauren Brown, Stephen Barnett, Deme Karikios
Editor's Note (June 2026): This episode was recorded prior to Australia's broad PBS listing of nivolumab and ipilimumab, which has removed the previous "once in a lifetime" restriction on immunotherapy. For the latest discussion on these changes and what they mean for lung cancer care, see our recent Conversations in Lung Cancer Research episodes on the broad immunotherapy listing. Support TOGAThank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify.---------------Connect with TOGAAttend an Event: https://thoraciconcology.org.au/events/Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/Follow UsLinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/X (Twitter): https://x.com/TOGAANZInstagram: https://www.instagram.com/togaanz/YouTube: https://www.youtube.com/@Thoracic_Oncology---------------Acknowledgement of CountryThe Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.
Embed this episode
What this episode covers
Our latest podcast explores the case for IO in early-stage NSCLC in our once in a lifetime world – the current Australian context. We review the medical oncology and surgical perspective of the current evidence for clinical benefit and what we have available in Australia. As clinicians, we are trained to give our best treatment up front, so patient discussion is important in an environment where we can only prescribe IO therapy once during the patient’s lung cancer disease. Dr Deme Karikios, Medical Oncologist from Nepean Hospital and Co-Chair of the Oncology Drugs Working Group is joined by Dr Lauren Brown, Medical Oncologist and Research Fellow at Nepean, Blacktown & Westmead Hospitals and Dr Stephen Barnett, Cardiothoracic Surgeon at the Austin Hospital, Peter MacCallum, Royal Melbourne and Western General Hospitals. CheckMate816: https://www.nejm.org/doi/full/10.1056/NEJMoa2202170 IMpower010: https://www.annalsofoncology.org/article/S0923-7534(23)00764-0/fulltext Neotorch: https://jamanetwork.com/journals/jama/fullarticle/2813880 Keynote671: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01756-2/abstract AGEAN: https://www.nejm.org/doi/full/10.1056/NEJMoa2304875 CheckMate770: https://www.nejm.org/doi/full/10.1056/NEJMoa2311926
NOW PLAYING
Hit It With Your Best Shot- The Case for IO in Early-Stage NSCLC in a Once in a Lifetime World
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.